Casey Ager

Assistant Professor

Mayo Clinic Arizona
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

We report the optimization of a 38‐parameter spectral flow cytometry panel to identify, phenotype, and assess lineage plasticity of human regulatory T cells (Tregs). Tregs are an indispensable T cell lineage with pleiotropic tolerogenic functions whose activities contribute critically to numerous disease settings including cancer, autoimmunity, and infectious disease, among others. Phenotypic and functional heterogeneity within the Treg lineage has been appreciated, but the etiology and impact of Treg plasticity across disease states remain incompletely understood. Better tools are thus needed to deeply characterize human Treg phenotypic heterogeneity at the single cell level to advance discovery of Treg‐based biomarkers in disease and to assess the effects of Treg‐directed therapeutics. To this end, our 38‐parameter panel consists of a 13‐marker PBMC backbone module to broadly phenotype PBMCs while specifically discriminating Tregs, and a 25‐marker Treg phenotyping module to determine Treg differentiation state, activation profile, and lineage subtype. In contrast to many high‐parameter OMIPs that rely on surface staining only, we incorporated several intracellular targets in this panel. This afforded the opportunity to thoroughly evaluate binding characteristics of all antibodies in both pre‐fixation and post‐fixation and permeabilization settings; we identify several antibodies eligible for overnight post‐fixation staining that require substantially reduced titers as compared to traditional pre‐fixation staining, resulting in significant cost savings. Dimensionality reduction and semi‐supervised clustering on healthy donor PBMC‐derived Tregs profiled by our panel reveal up to 14 discrete Treg phenotypes. In sum, this panel enables deep phenotypic characterization of human Treg heterogeneity in peripheral blood specimens by spectral flow cytometry.

Year:

2025

Despite high rates of post-surgical recurrence in men with high-risk localized prostate cancer (PCa), there is currently no role for neoadjuvant therapy. Tumor infiltrating regulatory T cells (TI-Tregs) limit the antitumor effects of presurgical androgen deprivation therapy (ADT). Therefore, we designed a neoadjuvant clinical trial to test whether Treg depletion via a non-fucosylated anti-CTLA-4 antibody (BMS-986218) is feasible and augments response to ADT. In this single-center, two-arm, open-label study, 24 men with high-risk localized PCa were randomized to ADT with or without BMS-986218 prior to radical prostatectomy. Treatment was well tolerated and feasible. Mechanistic studies indicated BMS-986218 depleted TI-Tregs by engaging CD16a/FCGR3A on tumor macrophages, modulated dendritic cells (DCs), and augmented T cell priming. Depth of Treg depletion and increased DC frequencies were quantitatively associated with improved clinical outcome. Overall, this study supports the feasibility and biological activity of neoadjuvant immunotherapy with ADT + Fc- enhanced anti-CTLA-4 in high-risk localized PCa. Statement of Significance Next-generation antibodies targeting CTLA-4 have been engineered for enhanced tumor Treg depletion in patients, yet their mechanisms of action remain incompletely defined. We performed the first single cell multi-omic correlative analyses of response to a glycoengineered anti-CTLA-4 antibody and defined mechanisms associated with clinical outcome in patients with high-risk localized prostate cancer.

Year:

2024

Lack of robust activation of Stimulator of Interferon Genes (STING) pathway and subsequent induction of type I IFN responses is considered a barrier to antitumor immunity in acute myeloid leukemia (AML). Using common human AML cell lines as in vitro tools to evaluate the efficacy of novel STING agonists, we found most AML lines to be poor producers of IFNs upon exposure to extremely potent agonists, suggesting cell-intrinsic suppression of STING signaling may occur. We observed unexpected patterns of response that did not correlate with levels of STING pathway components or of known enzymes associated with resistance. To identify a genetic basis for these observations, we cloned and sequenced STING from the cDNA of human AML cell lines and found both frequent mutations and deviations from normal RNA splicing. We identified two novel spliced isoforms of STING in these lines and validated their expression in primary human AML samples. When transduced into reporter cells, these novel STING isoforms exhibited complete insensitivity to agonist stimulation. These observations identify alternative splicing as a mechanism of STING pathway suppression and suggest that most AML silences the STING pathway through direct modification rather than through engagement of external inhibitory factors. Significance: We find that AML acquires resistance to innate immune activation via the STING pathway through aberrant splicing of the STING transcript including two novel forms described herein that act as dominant negatives. These data broaden understanding of how cancers evolve STING resistance, and suggest that the AML tumor microenvironment, not the cancer cell, should be the target of therapeutic interventions to activate STING.

Year:

2024

Evaluating activity of novel STING agonists on alternate STING isoforms. A total of 5 × 10 4 HEK-Blue reporter cells expressing indicated STING alleles were incubated with 100 µg/mL CDN for 24 hours. IRF3/9 activity was measured by secreted alkaline phosphatase (SEAP) assay. IFNα positive control indicates presence and functionality of the IRF3/9 SEAP reporter in these cells. Statistical significance was calculated using repeated measures one-way ANOVA ( n = 2). ns, not significant; *, P P P P

Year:

2024

Identification of STING germline and transcript variants in AML. A, Summary of sequencing results indicating identification of known STING variant alleles and novel spliced isoforms. B, Structure of STING genomic locus and annotated coding sequence maps for WT, STING-I3R, and STING-Ex4D. Identification and validation of STING-I3R allele in primary bone marrow aspirates ( C ) and in normal donors ( D ) using primers to selectively amplify WT or I3R STING alleles.

Year:

2024

Evaluation of the STING pathway across common AML cell lines. A, Indicated AML cell lines plated 1 × 10 5 cells/well were stimulated 72 hours with CDNs at 10 µg/mL, and supernatants were harvested for ELISA ( n = 5). An assay detection limit of 50 pg/mL is shown. qPCR analysis ( B ) and immunoblot ( C ) of STING pathway and resistance genes across AML lines ( n = 1). For qPCR, data represent GAPDH-normalized fold expression relative to normal CD11b + PBMC controls.

Year:

2024

Novel STING alleles fail to respond to STING agonists. HEK-Blue-ISG-KO-STING cells were reconstituted with indicated novel STING variants ( n = 2; A ) or STING variants plus WT STING by retroviral transduction ( B ), then were exposed to 100 µg/mL indicated CDN for 24 hours ( n = 2). IRF3/9 activity was measured by SEAP assay. IFNα positive control indicates presence and functionality of the IRF3/9 SEAP reporter in these cells. Statistical significance in B was calculated using repeated measures one-way ANOVA test. ns, not significant; *, P P P P C, STING knockout 293 T cells were transduced to express human WT STING with an HA or 6xHIS tag, the STING-I3R isoform with a 6xHIS tag, or the STING-Ex4D isoform with a 6xHIS tag. Cell lysates were Western blotted with anti-6xHIS antibody (Invitrogen) followed by anti-mouse HRP (Cell Signaling Technology). Anti-human β-actin staining is shown as a loading control (Abcam).

Year:

2024

Identification of STING germline and transcript variants in AML. A, Summary of sequencing results indicating identification of known STING variant alleles and novel spliced isoforms. B, Structure of STING genomic locus and annotated coding sequence maps for WT, STING-I3R, and STING-Ex4D. Identification and validation of STING-I3R allele in primary bone marrow aspirates ( C ) and in normal donors ( D ) using primers to selectively amplify WT or I3R STING alleles.

Year:

2024

Novel STING alleles fail to respond to STING agonists. HEK-Blue-ISG-KO-STING cells were reconstituted with indicated novel STING variants ( n = 2; A ) or STING variants plus WT STING by retroviral transduction ( B ), then were exposed to 100 µg/mL indicated CDN for 24 hours ( n = 2). IRF3/9 activity was measured by SEAP assay. IFNα positive control indicates presence and functionality of the IRF3/9 SEAP reporter in these cells. Statistical significance in B was calculated using repeated measures one-way ANOVA test. ns, not significant; *, P P P P C, STING knockout 293 T cells were transduced to express human WT STING with an HA or 6xHIS tag, the STING-I3R isoform with a 6xHIS tag, or the STING-Ex4D isoform with a 6xHIS tag. Cell lysates were Western blotted with anti-6xHIS antibody (Invitrogen) followed by anti-mouse HRP (Cell Signaling Technology). Anti-human β-actin staining is shown as a loading control (Abcam).

Year:

2024

Evaluating activity of novel STING agonists on alternate STING isoforms. A total of 5 × 10 4 HEK-Blue reporter cells expressing indicated STING alleles were incubated with 100 µg/mL CDN for 24 hours. IRF3/9 activity was measured by secreted alkaline phosphatase (SEAP) assay. IFNα positive control indicates presence and functionality of the IRF3/9 SEAP reporter in these cells. Statistical significance was calculated using repeated measures one-way ANOVA ( n = 2). ns, not significant; *, P P P P

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Michael A. Curran

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Guarionex Joel DeCastro

Associate Professor

Columbia University

UNITED STATES
View details

Mark Stein

Associate Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Gheath Alatrash

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details